Furthermore, inhaled VIP administered in a clinical trial for sarcoidosis patients was found to significantly increase the numbers of CD4+CD127−CD25+ FOXP3+ T cells in the BAL [51]. The gene discussed is FOXP3; the disease is sarcoidosis.